ALKS - Alkermes plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
ALKS price evolution
ALKS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $535.15 | $420.75 | $457.47 | |
| Short term investments | $340.97 | $324.3 | $316.02 | |
| Net receivables | $370.18 | $366.42 | $315.85 | $332.48 |
| Inventory | $191.09 | $194.73 | $198.37 | $186.41 |
| Total current assets | $1564.18 | $1542.19 | $1468.83 | $1485.51 |
| Long term investments | $86.4 | $62.78 | $39.89 | |
| Property, plant & equipment | $311.5 | $310.63 | $314.27 | $318.4 |
| Goodwill & intangible assets | $83.94 | $83.96 | $85.02 | |
| Total noncurrent assets | $664.65 | $655.07 | $650.72 | |
| Total investments | $427.37 | $387.08 | $355.91 | |
| Total assets | $2155.29 | $2206.84 | $2123.9 | $2136.22 |
| Current liabilities | ||||
| Accounts payable | $37.04 | $239.77 | $205.85 | $240.56 |
| Deferred revenue | ||||
| Short long term debt | $9.01 | $8.91 | $8.75 | |
| Total current liabilities | $453.7 | $515.55 | $458.98 | $520.22 |
| Long term debt | $285.82 | $358.99 | $361.2 | $363.44 |
| Total noncurrent liabilities | $407.29 | $410.16 | $413.32 | |
| Total debt | $368 | $370.11 | $372.19 | |
| Total liabilities | $863.18 | $922.84 | $869.13 | $933.54 |
| Shareholders' equity | ||||
| Retained earnings | -$1122.96 | -$1215.34 | -$1306.7 | -$1343.53 |
| Other shareholder equity | $0.42 | -$3.59 | -$3.6 | -$3.11 |
| Total shareholder equity | $1284.01 | $1254.76 | $1202.69 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $457.47 | $292.47 | $337.54 | $272.96 |
| Short term investments | $316.02 | $315.99 | $198.77 | $362.07 |
| Net receivables | $332.48 | $296.9 | $313.19 | $275.14 |
| Inventory | $186.41 | $181.42 | $150.34 | $125.74 |
| Total current assets | $1485.51 | $1130.31 | $1062.17 | $1110.97 |
| Long term investments | $39.89 | $131.61 | $229.43 | $24.78 |
| Property, plant & equipment | $318.4 | $441.22 | $456.68 | $481.72 |
| Goodwill & intangible assets | $85.02 | $130.55 | $166.92 | $204.06 |
| Total noncurrent assets | $650.72 | $833.67 | $962.32 | $838.76 |
| Total investments | $355.91 | $447.6 | $428.2 | $386.85 |
| Total assets | $2136.22 | $1963.98 | $2024.48 | $1949.73 |
| Current liabilities | ||||
| Accounts payable | $240.56 | $32.84 | $445.71 | $412.17 |
| Deferred revenue | $7.51 | |||
| Short long term debt | $8.75 | $18.72 | $19.24 | $18.57 |
| Total current liabilities | $520.22 | $497.74 | $471.29 | $438.26 |
| Long term debt | $363.44 | $290.27 | $396.97 | $391.58 |
| Total noncurrent liabilities | $413.32 | $422.48 | $440.61 | $444.49 |
| Total debt | $372.19 | $398.82 | $416.21 | $410.16 |
| Total liabilities | $933.54 | $920.23 | $911.9 | $882.75 |
| Shareholders' equity | ||||
| Retained earnings | -$1343.53 | -$1699.29 | -$1541.02 | -$1492.85 |
| Other shareholder equity | -$3.11 | -$10.89 | -$3.72 | -$1.35 |
| Total shareholder equity | $1202.69 | $1043.75 | $1112.58 | $1066.98 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $399.13 | $350.37 | $377.48 | |
| Cost of revenue | $61.47 | $58.64 | $70.09 | |
| Gross Profit | $337.66 | $291.73 | $307.38 | |
| Operating activities | ||||
| Research & development | $59.65 | $67.61 | -$20.76 | |
| Selling, general & administrative | $168.11 | $179.75 | $140.57 | |
| Total operating expenses | $227.78 | $248.42 | $128.81 | |
| Operating income | $109.88 | $43.31 | $178.57 | |
| Income from continuing operations | ||||
| EBIT | $119.37 | $50.77 | $24.91 | |
| Income tax expense | $22.06 | $7.96 | -$93.92 | |
| Interest expense | $5.95 | $5.98 | $6.05 | |
| Net income | ||||
| Net income | $91.36 | $36.83 | $112.78 | |
| Income (for common shares) | $91.36 | $36.83 | $112.78 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1663.4 | $1111.8 | $1173.75 | $1038.76 |
| Cost of revenue | $253.04 | $218.11 | $197.39 | $178.32 |
| Gross Profit | $1410.37 | $893.69 | $976.36 | $860.44 |
| Operating activities | ||||
| Research & development | $270.81 | $393.84 | $406.53 | $394.59 |
| Selling, general & administrative | $689.75 | $605.75 | $560.98 | $538.83 |
| Total operating expenses | $996.25 | $1035.95 | $1005.65 | $972.87 |
| Operating income | $414.12 | -$142.26 | -$29.29 | -$112.43 |
| Income from continuing operations | ||||
| EBIT | $281.15 | -$154.26 | -$28.09 | -$87.88 |
| Income tax expense | -$97.64 | -$9.04 | $8.86 | $14.32 |
| Interest expense | $23.03 | $13.04 | $11.22 | $8.66 |
| Net income | ||||
| Net income | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| Income (for common shares) | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $91.36 | $36.83 | $112.78 | |
| Operating activities | ||||
| Depreciation | $6.66 | $8.06 | $18.54 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $20.6 | $32.76 | $25.84 | |
| Total cash flows from operations | $146.03 | $21.11 | $107.24 | |
| Investing activities | ||||
| Capital expenditures | $90.84 | -$7.93 | -$16.68 | |
| Investments | -$38.99 | -$32.02 | -$4.3 | |
| Total cash flows from investing | -$97.43 | $51.85 | -$39.95 | -$20.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$82.08 | $11.23 | $1.65 | |
| Net borrowings | -$0.75 | -$0.75 | -$0.75 | |
| Total cash flows from financing | -$212.47 | -$83.48 | -$17.87 | -$276.5 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$61.18 | $114.4 | -$36.72 | -$190.24 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| Operating activities | ||||
| Depreciation | $74.93 | $77.86 | $78.65 | $81.85 |
| Business acquisitions & disposals | $1.76 | $7.94 | $6.64 | |
| Stock-based compensation | $100.91 | $94.25 | $87.62 | $90.16 |
| Total cash flows from operations | $401.35 | $21.04 | $101.72 | $82.84 |
| Investing activities | ||||
| Capital expenditures | -$47.69 | -$38.26 | -$27.73 | -$41.58 |
| Investments | $101.05 | -$28.04 | -$45.41 | $23.46 |
| Total cash flows from investing | $53.36 | -$64.54 | -$66.2 | -$11.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.76 | $19.63 | $25.32 | $8.37 |
| Net borrowings | -$3 | -$3 | $20.32 | -$2.84 |
| Total cash flows from financing | -$289.71 | -$1.57 | $29.07 | -$2.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $165 | -$45.07 | $64.58 | $69.19 |
News
Fundamentals
| Market cap | $5.12B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 161.78M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.78 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.45 |
| Quick ratio | 3.03 |